Table 1. Patient characteristics of the three cohorts used in CTC profile discovery and validation.
| Characteristic | Group | Training Cohort | Validation Cohort 1 | Validation Cohort 2 |
| Total number | 72 | 49 | 123 | |
| Age | <40 | 5 (6.9%) | 6 (12.2%) | 32 (26.0%) |
| 40–50 | 22 (30.6%) | 5 (10.2%) | 71 (57.7%) | |
| 50–60 | 28 (38.9%) | 11 (22.4%) | 20 (16.3%) | |
| 60+ | 17 (23.6%) | 27 (55.1%) | 0 (0%) | |
| Tumor Size | pT1 (≤20 mm) | 47 (65.3%) | 25 (51%) | 48 (39.0%) |
| pT2 (20–50 mm) | 17 (23.1%) | 22 (44.9%) | 73 (59.4%) | |
| pT3 (>50 mm) | 8 (11.1%) | 0 (0%) | 2 (1.6%) | |
| Unknown | 0 (0%) | 2 (4.1%) | 0 (0%) | |
| Histological grade | I | 15 (20.8%) | 8 (16.3%) | 30 (24.4%) |
| II | 37 (51.4%) | 28 (57.1%) | 37 (30.1%) | |
| III | 18 (25.0%) | 13 (26.5%) | 56 (45.5%) | |
| Unknown | 2 (2.8%) | 0 (0%) | 0 (0%) | |
| HR status | Negative | 12 (16.7%) | 17 (34.7%) | 40 (32.5%) |
| Positive | 58 (80.6%) | 31 (63.3%) | 83 (67.5%) | |
| Unknown | 2 (2.8%) | 1 (2.0%) | 0 (0%) | |
| HER2/NEU status | Negative | 54 (75%) | 38 (77.6%) | 93(75.6%) |
| Positive | 16 (22.2%) | 8 (16.3%) | 22 (17.9%) | |
| Unknown | 2 (2.8%) | 3 (6.1%) | 8 (6.5%) | |
| CTC status | Positive | 31 (43.1%) | 8 (16.3%) | Not Determined |
| Negative | 41 (56.9%) | 41 (83.7%) | ||
| CTC profile | Positive | 29 (40.3%) | 18 (36.7%) | 81 (65.9%) |
| Negative | 43 (59.7%) | 31 (63.3%) | 42 (34.1%) | |
| MammaPrint | High-risk | Not Determined | Not Determined | 62 (50.8%) |
| Low-risk | 60 (49.2%) |